These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 23714473

  • 1. How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
    van den Bent MJ.
    Am Soc Clin Oncol Educ Book; 2013; ():114-6. PubMed ID: 23714473
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
    Buckner JC, Gesme D, O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R.
    J Clin Oncol; 2003 Jan 15; 21(2):251-5. PubMed ID: 12525516
    [Abstract] [Full Text] [Related]

  • 4. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR, Dietrich J, Atkins KM, Oh KS, Loeffler JS, Shih HA.
    Cancer Med; 2020 Jan 15; 9(1):3-11. PubMed ID: 31701682
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ.
    Cancer; 2005 Feb 15; 103(4):802-9. PubMed ID: 15637687
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN.
    J Natl Cancer Inst; 1998 Oct 07; 90(19):1473-9. PubMed ID: 9776413
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
    Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M.
    J Clin Oncol; 2013 Jan 20; 31(3):337-43. PubMed ID: 23071247
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.
    Polivka J, Polivka J, Repik T, Rohan V, Hes O, Topolcan O.
    Anticancer Res; 2016 Jan 20; 36(1):471-6. PubMed ID: 26722084
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
    Roth P, Wick W, Weller M.
    Curr Treat Options Oncol; 2013 Dec 20; 14(4):505-13. PubMed ID: 23907441
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A, German Glioma Network.
    Clin Cancer Res; 2007 Dec 01; 13(23):6933-7. PubMed ID: 18056167
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.